Number of patient samples affected before error detection: Strategic implications for internal quality control and patient-based quality control practices.
{"title":"Number of patient samples affected before error detection: Strategic implications for internal quality control and patient-based quality control practices.","authors":"Hui Qi Low, Corey Markus, Tze Ping Loh, Chun Yee Lim","doi":"10.1016/j.cca.2025.120166","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>There is a general impression that patient-based quality control (PBQC) requires a high volume of laboratory results to detect errors effectively. However, internal quality control (IQC) performed infrequently may be associated with increased risk of missed error (i.e. low power of error detection).</p><p><strong>Methods: </strong>Using simulations and routine sodium and aspartate aminotransferase (AST) as examples, this study examined how the \"average number of patient samples affected before error detection' (ANPed) metrics can provide linkage to compare relative performance of QC practices in various IQC and PBQC settings.</p><p><strong>Results: </strong>Smaller numbers of IQC samples tested per IQC run or larger average number of patient samples measured between IQC runs are associated with higher ANPed. The ANPed for sodium and AST PBQC models were smaller than IQC performed once every 100 patient samples, except when the systematic error was small for AST.</p><p><strong>Discussion: </strong>Use of ANPed clearly illustrate the relative impact of different IQC frequencies and number of IQC levels tested. Patient-based quality control can outperform IQC even for laboratories with small testing volume. Laboratory practitioners can use this metric to design a QC strategy that suit their desired risk profile.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120166"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cca.2025.120166","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: There is a general impression that patient-based quality control (PBQC) requires a high volume of laboratory results to detect errors effectively. However, internal quality control (IQC) performed infrequently may be associated with increased risk of missed error (i.e. low power of error detection).
Methods: Using simulations and routine sodium and aspartate aminotransferase (AST) as examples, this study examined how the "average number of patient samples affected before error detection' (ANPed) metrics can provide linkage to compare relative performance of QC practices in various IQC and PBQC settings.
Results: Smaller numbers of IQC samples tested per IQC run or larger average number of patient samples measured between IQC runs are associated with higher ANPed. The ANPed for sodium and AST PBQC models were smaller than IQC performed once every 100 patient samples, except when the systematic error was small for AST.
Discussion: Use of ANPed clearly illustrate the relative impact of different IQC frequencies and number of IQC levels tested. Patient-based quality control can outperform IQC even for laboratories with small testing volume. Laboratory practitioners can use this metric to design a QC strategy that suit their desired risk profile.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.